CRK SH3N Domain Diminishes Cell Invasiveness of Non-Small Cell Lung Cancer
Related Experiment Video
Updated: May 6, 2026

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
Gholam H Pezeshkpour1, Farhad Moatamed, Michael Lewis
1Department of Pathology, West Los Angeles VA, Los Angeles, CA, USA.
Abstract:
CRK (c-Crk) as an adaptor protein is involved in several oncogenic signal transduction pathways, conveying oncogenic signals to its downstream effectors and thereby affecting multiple cellular processes including proliferation, differentiation, and migration. For example, we have observed that CRK expression and phosphorylation influence the invasiveness of non-small cell lung cancer (NSCLC) cells. To intervene in CRK signaling pathway, we examined whether CRK protein domains can be used as therapeutic tools to interrupt CRK signaling, thus influencing the biological behavior of NSCLC cells. For this purpose, Src Homology domains of CRK-I (i.e., SH2 and SH3N domains) were overexpressed in H157, Rh2, and A549 cells. CRK-SH3N domain expression induced epithelial morphology in H157 cells and enhanced epithelial morphology of A549 and Rh2 cells as compared to cells transfected with CRK-SH2 domain or empty vector. In addition, CRK-SH3N domain expression significantly decreased the motility and invasiveness of A549 and H157 cells. Furthermore, CRK-SH3N domain expression disrupted the interaction of CRK-II with DOCK180. In summary, these data provide evidence that the CRK-SH3N domain can be used to influence the malignant phenotype of NSCLC cells and also reduce the metastatic potential of these cells.
Insights
The CRK-SH3N domain can reduce non-small cell lung cancer (NSCLC) cell invasiveness and malignant phenotype. This adaptor protein domain offers a potential therapeutic strategy to decrease NSCLC metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- CRK (c-Crk) adaptor protein regulates oncogenic signaling pathways.
- CRK expression and phosphorylation impact non-small cell lung cancer (NSCLC) cell invasiveness.
- Targeting CRK signaling may offer therapeutic interventions for NSCLC.
Purpose of the Study:
- To investigate the therapeutic potential of CRK protein domains in NSCLC.
- To determine if CRK domains can interrupt CRK signaling and influence NSCLC cell behavior.
- To evaluate the effects of CRK-SH2 and CRK-SH3N domains on NSCLC cell lines.
Main Methods:
- Overexpression of CRK-SH2 and CRK-SH3N domains in H157, Rh2, and A549 NSCLC cells.
- Assessment of cellular morphology, motility, and invasiveness.
- Analysis of the interaction between CRK-II and DOCK180.
Main Results:
- CRK-SH3N domain expression induced and enhanced epithelial morphology in NSCLC cells.
- CRK-SH3N domain significantly reduced the motility and invasiveness of A549 and H157 cells.
- CRK-SH3N domain expression disrupted the CRK-II and DOCK180 interaction.
Conclusions:
- The CRK-SH3N domain can modulate the malignant phenotype of NSCLC cells.
- CRK-SH3N domain expression shows potential in reducing the metastatic capacity of NSCLC.
- CRK protein domains represent promising therapeutic tools for NSCLC treatment.
More Related Videos
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
08:12The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior
Published on: June 12, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...